Preclinical models of multiple myeloma: A critical appraisal

Expert Opinion on Biological Therapy

Volumn 13, Issue SUPPL.1, 2013, Pages

  Schüler, Julia ^a   Ewerth, Daniel ^a   Waldschmidt, Johannes ^a   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

2D 3D in vitro culture; Animal models; Co culture; in vivo imaging; Multiple myeloma; NOD SCID; Novel agent drug development; NSG

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; HISTONE DEACETYLASE INHIBITOR; PLERIXAFOR; POMALIDOMIDE; PROTEASOME INHIBITOR; SORAFENIB;

CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CANCER RESISTANCE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; LIQUID CULTURE; MULTIPLE MYELOMA; NONHUMAN; REVIEW; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MULTIPLE MYELOMA;

ANIMALIA;

EID: 84879572309     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.799131     Document Type: Review

References (100)

1. Palumbo A, Cavallo F. Have drug combinations supplanted stem cell transplantation in myeloma? ASH Education Program Book 2012;2012:335-41
2. Engelhardt M, Udi J, Kleber M, et al. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010;51:2006-11
3. Kleber M, Udi J, Metzke B, et al. Challenging the current approaches to multiple myeloma-and other cancer-related bone diseases: from bisphosphonates to targeted therapy. Leuk Lymphoma 2012;53:1057-61
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9
5. Mullard A. 2011 in reflection. Nat Rev Drug Discov 2012;11:6-8
6. Rongvaux A, Takizawa H, Strowig T, et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol 2013;31:635-74
7. Udi J, Wider D, Kleber M, et al. Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments. Leuk Res 2011;35:1265-8
8. Zlei M, Egert S, Wider D, et al. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 2007;35:1550-61
9. DeWeerdt S. Animal models: towards a myeloma mouse. Nature 2011;480:S38-9
10. Vande Broek I, Vanderkerken K, Van Camp B, et al. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008;25:325-34
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
12. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31
13. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011;29:591-9
14. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009;114:1150-7
15. Shiozawa Y, Havens AM, Pienta KJ, et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008;22:941-50
16. Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci 1994;91:10148-52
17. Chen Q, Kinch MS, Lin TH, et al. Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J Biol Chem 1994;269:26602-5
18. Hanks SK, Calalb MB, Harper MC, et al. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci 1992;89:8487-91
19. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996;379:91-6
20. Kobune M, Chiba H, Kato J, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther 2007;6:1774-84
21. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113:4341-51
22. Berger LC, Hawley TS, Lust JA, et al. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys Res Commun 1994;202:596-605
23. Body J-J, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
24. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114:371-9
25. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27
26. Ogata A, Chauhan D, Urashima M, et al. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res 1997;3:1017-22
27. Sanz-Rodriguez F, Hidalgo A, Teixidó J. Chemokine stromal cell-derived factor-1a modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-51
28. Sneed TB, Stanley DJ, Young LA, et al. Interleukin-6 regulates expression of the syndecan-1 proteoglycan on B lymphoid cells. Cell Immunol 1994;153:456-67
29. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 2003;63:5850-8
30. Vincent T, Mechti N. IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 2004;18:967-75
31. Shain KH, Yarde DN, Meads MB, et al. b1 Integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009;69:1009-15
32. Damiano JS, Cress AE, Hazlehurst LA, et al. Cell Adhesion Mediated Drug Resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67
33. Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012;119:5782-94
34. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72
35. Kirshner J, Thulien KJ, Martin LD, et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008;112:2935-45
36. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011;117:4409-19
37. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010;10:241-53
38. Anderson KC. New insights into therapeutic targets in myeloma. ASH Educ Program Book 2011;2011:184-90
39. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8
40. Udi J, Schuler J, Wider D, et al. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol 2013;161(1):104-16
41. Zhu YX, Braggio E, Shi C-X, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9
42. Drewinko B, Alexanian R, Boyer H, et al. The growth fraction of human myeloma cells. Blood 1981;57:333-8
43. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005;105:4845-8
44. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-91
45. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104-12
46. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977;91:335-44
47. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008;112:159-68
48. Waldschmidt JW, Follo M, Udi J, et al. Bone marrow interaction in multiple myeloma pathogenesis: phenotypical analysis, kinetics and novel therapies based on CXCR4 inhibition. ASH Annual Meeting; Atlanta: Blood; 2012
49. Fulciniti M, Hideshima T, Vermot-Desroches C, et al. A High-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009;15:7144-52
50. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005;106:2472-83
51. Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010;51:213-20
52. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30
53. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18(22):6260-70
54. Zdzisinska B, Rolinski J, Piersiak T, et al. A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Folia Histochem Cytobiol 2009;47:69-74
55. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-7
56. Pilarski LM, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95:1056-65
57. Xue Y, Danmark S, Xing Z, et al. Growth and differentiation of bone marrow stromal cells on biodegradable polymer scaffolds: an in vitro study. J Biomed Mater Res Part A 2010;95:1244-51
58. Niemeyer P, Krause U, Fellenberg J, et al. Evaluation of mineralized collagen and alpha-tricalcium phosphate as scaffolds for tissue engineering of bone using human mesenchymal stem cells. Cells Tissues Organs 2004;177:68-78
59. Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res 2011;71:7141-4
60. de Jong M, Maina T. Of mice and humans: are they the same?-Implications in cancer translational research. J Nucl Med 2010;51:501-4
61. Manning LS, Berger JD, O'Donoghue HL, et al. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 1992;66:1088-93
62. Laronne-Bar-On A, Zipori D, Haran-Ghera N. Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma. J Immunol 2008;181:3714-24
63. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13:167-80
64. Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012;120:376-85
65. Sellers WR. A blueprint for advancing genetics-based cancer therapy. Cell 2011;147:26-31
66. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31
67. Macor P, Secco E, Zorzet S, et al. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008;14:2023-39
68. Landel CP, Dunlap J, Patton JB, et al. A germline-competent embryonic stem cell line from NOD.Cg-Prkdc (scid) Il2rg (tm1Wjl)/SzJ (NSG) mice. Transgenic Res 2013;22:179-85
69. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-82
70. Garg TK, Szmania SM, Khan JA, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 2012;97(9):1348-56
71. Swift BE, Williams BA, Kosaka Y, et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012;97(7):1020-8
72. McKenzie JL, Gan OI, Doedens M, et al. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood 2005;106:1259-61
73. Diamond P, Labrinidis A, Martin SK, et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 2009;24:1150-61
74. Notta F, Doulatov S, Laurenti E, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011;333:218-21
75. Libby SJ, Brehm MA, Greiner DL, et al. Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci USA 2010;107:15589-94
76. Pennisi A, Ling W, Li X, et al. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 2009;114:1803-12
77. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-13
78. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-82
79. Yaccoby S, Johnson CL, Mahaffey SC, et al. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002;100:4162-8
80. Yang Y, MacLeod V, Dai Y, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007;110:2041-8
81. Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001;2:42-53
82. Qiang Y-W, Shaughnessy JD, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008;112:374-82
83. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-16
84. Yang Y, MacLeod V, Bendre M, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005;105:1303-9
85. Li X, Ling W, Khan S, et al. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res 2012;27:1635-48
86. Li X, Ling W, Pennisi A, et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells 2011;29:263-73
87. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-11
88. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004;18:1891-7
89. Calimeri T, Battista E, Conforti F, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011;25:707-11
90. Groen RW, Noort WA, Raymakers RA, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012;120:e9-e16
91. Yang XB, Bhatnagar RS, Li S, et al. Biomimetic collagen scaffolds for human bone cell growth and differentiation. Tissue Eng 2004;10:1148-59
92. Muller J, Wunder A, Licha K. Optical imaging. Recent Results Cancer Res 2013;187:221-46
93. Wolf G, Abolmaali N. Preclinical molecular imaging using PET and MRI. Recent Results Cancer Res 2013;187:257-310
94. Brennan SK, Wang Q, Tressler R, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010;5:e12487
95. Mezzanotte L, Que I, Kaijzel E, et al. Sensitive dual color in vivo bioluminescence imaging using a new red codon optimized firefly luciferase and a green click beetle luciferase. PLoS One 2011;6:e19277
96. Deuschle U, Schuler J, Schulz A, et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One 2012;7:e43044
97. Wehr C, Muller F, Schuler J, et al. Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. Int J Cancer 2012;131:E10-20
98. Edwards WB, Akers WJ, Ye Y, et al. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imaging 2009;8:101-10
99. Pesnel S, Pillon A, Créancier L, et al. Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody. PLoS ONE 2012;7:e30690
100. Podar K, Anderson KC. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 2011;11:1005-24